Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

類似資料

• P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
  著者:: Paolo F Caimi, 等
  出版事項: (2023-08-01)
• PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
  著者:: M. Hamadani, 等
  出版事項: (2022-06-01)
• Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
  著者:: Fateeha Furqan, 等
  出版事項: (2022-03-01)
• P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)
  著者:: A. Spira, 等
  出版事項: (2022-06-01)
• Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma
  著者:: Riyad N.H. Seervai, MD, PhD, 等
  出版事項: (2024-11-01)